Rime Bioinformatics

Rime Bioinformatics

Paris, France· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.8M

Overview

Rime Bioinformatics is a Paris-based service provider that addresses the technical and computational barriers faced by biologists in analyzing DNA/RNA sequencing data. The company's core mission is to democratize access to precise, high-quality bioinformatics, enabling faster research and development, particularly in the field of phage therapy. By developing and benchmarking advanced tools and delivering clear, biologist-friendly reports, Rime aims to accelerate the development of safer alternatives to antibiotics across human health, agriculture, and veterinary medicine.

Infectious DiseaseAntimicrobial Resistance

Technology Platform

Integrated service platform combining continuous benchmarking of public bioinformatics tools, development of proprietary analysis methods (especially for phage/microbial genomes), and delivery via high-performance computing, resulting in biologist-friendly analytical reports.

Funding History

1
Total raised:$1.8M
Seed$1.8M

Opportunities

The global antimicrobial resistance crisis creates urgent demand for alternatives like phage therapy, which requires mandatory, in-depth genomic analysis.
The widespread adoption of sequencing technology across life sciences generates a vast and growing need for accessible, high-performance bioinformatics expertise that many research teams lack internally.

Risk Factors

The company faces competition from other bioinformatics service providers and internal academic cores.
Its growth is heavily dependent on the pace and success of the broader phage therapy field.
Maintaining a technological edge in a rapidly evolving software landscape is an ongoing execution challenge.

Competitive Landscape

Rime competes in the bioinformatics services market, which includes contract research organizations (CROs), academic core facilities, freelance bioinformaticians, and bioinformatics software companies. Its differentiation lies in its specialized expertise in phage genomics and its focus on making advanced analyses accessible to biologists without computational backgrounds.